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 Minimally invasive intervention strategies after myocardial infarction use 
state-of-the-art catheter systems that are able to combine mapping of the inf-
arcted area with precise, local injection of drugs. To this end, catheter delivery 
of drugs that are not immediately pumped out of the heart is still chal-
lenging, and requires a carrier matrix that in the solution state can be injected 
through a long catheter, and instantaneously gelates at the site of injection. 
To address this unmet need, a pH-switchable supramolecular hydrogel is 
developed. The supramolecular hydrogel is switched into a liquid at pH  > 8.5, 
with a viscosity low enough to enable passage through a 1-m long catheter 
while rapidly forming a hydrogel in contact with tissue. The hydrogel has 
self-healing properties taking care of adjustment to the injection site. Growth 
factors are delivered from the hydrogel thereby clearly showing a reduction of 
infarct scar in a pig myocardial infarction model. 
yield a further rise in mortality and mor-
bidity. [ 1 ] New strategies are aiming at the 
prevention of the progression of postmy-
ocardial infarction toward heart failure. 
Catheter-based drug delivery injection 
approaches [ 2 , 3 ] are substantially less inva-
sive than for example surgical implan-
tation of in vitro engineered tissues, [ 4 ] 
patches, [ 5 , 6 ] or drug delivery carriers. [ 7 ] 
Therefore, catheter-injection strategies 
are the method of choice with regard to 
clinical applicability. State-of-the-art is the 
NOGA catheter that enables precise con-
trol over the injection location via a special 
mapping system. [ 8 ] A 3D electromechan-
ical image of the myocardium can be 
obtained using an ultralow magnetic-fi eld 
energy source and a sensor-tipped cath-
eter to locate the catheter position. This 
mapping allows for the accurate identifi cation of normal and 
infarcted myocardium, and in this way, enables excellent spatial 
control over the injection of drugs. Generally, the injected drugs 
are substantially fast removed from the pulsatile heart when not 
delivered via a solid or gelated carrier material. Therefore, the 
 1. Introduction 
 Coronary artery disease is a progressive disease that can be 
held responsible for over seven million deaths worldwide 
each year, and the increased aging of the population will even 
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development of carrier materials that can be injected through 
the extremely long and narrow lumen of such catheters, and 
instantaneously gelate in contact with the myocardial tissue, 
is prerequisite. The dimensions of the catheters, combined 
with the dynamic beating environment of the heart, require a 
material with Janus-like material properties; i.e., low viscosity 
to fl ow through the long, narrow lumen of the catheter, and 
high stability to form a local drug delivery reservoir and pro-
vide mechanical support in the tissue after injection. This dual 
character is proposed to be obtained using a stimuli-responsive, 
switchable hydrogel. Furthermore, ideally, this hydrogel shows 
self-healing properties within the high shear environment of 
the contracting heart muscle. 
 Natural hydrogels for myocardial injection therapies that 
have been investigated include fi brin, [ 9 ] collagen, [ 10 ] alginate, [ 11 ] 
Matrigel, [ 12 ] hyaluronic acid, [ 13 ] and chitosan. [ 14 ] These hydro-
gels can potentially be delivered in combination with cells 
or drugs, however, they are derived from a natural source 
and therefore show batch-to-batch differences. Furthermore, 
their switching behavior can be poorly controlled. As a conse-
quence, although injection of these hydrogels via a syringe was 
accomplished relatively easily, the translation to catheter-based 
delivery has yet remained an unmet challenge. Recently, decel-
lularized porcine extracellular matrix (ECM)-derived hydrogels 
have been reported as catheter-injectable scaffolds for cardiac 
regeneration. [ 15 ] However, these ECM-derived hydrogels did not 
show very fast gelation upon injection, and their compatibility 
with clinical use will be poor because of their animal origin. 
We propose that synthetic materials fulfi ll the extensive list of 
requirements, amongst others that they do not show batch-to-
batch differences, they are more easy to switch from sol–gel, 
and they are not animal, bacteria, or carcinoma derived. [ 16 ] 
Several synthetic systems have been explored for cardiac injec-
tion today, including self-assembling peptides [ 17 ] and synthetic 
hydrogels that are formed after injection via in situ chemical 
or physical cross-linking, [ 18 ] photo-induced polymerization, [ 19 ] 
self-assembly, [ 20 ] or thermal switching. [ 21 ] Again, although easy 
syringe injection can be obtained with these systems, catheter 
compatibility remains diffi cult and has not been shown. 
 Differences in pH form interesting parameters to induce 
switchable behavior in material properties. Since variations 
of pH naturally occur in the human body, exploiting these for 
hydrogel formation is appealing. Various pH-responsive sys-
tems appear throughout literature. Importantly, the vast amount 
of pH-responsive systems are used to enable controlled release 
of hydrogel payload rather than used to persue a switch in mate-
rial properties thereby controlling catheter-guided injection. [ 22 ] 
 Synthetic supramolecular hydrogelators [ 23–29 ] that are held 
together by directed, noncovalent interactions are proposed to 
allow for full control of their sol–gel switching behavior under 
mild conditions using the dynamic nature of the supramo-
lecular interactions. When exploited to the fullest, supramo-
lecular switchable hydrogels systems might be the solution 
for future clinical catheter-delivery therapies. Therefore, our 
approach to a synthetic, catheter-injectable hydrogel uses the 
fourfold hydrogen bonding supramolecular ureido-pyrimid-
inone (UPy) units [ 30 ] coupled via alkyl-urea spacers to 10k or 
20k poly(ethylene glycol) (PEG) chains ( Figure 1 A ). [ 31 , 32 ] These 
UPy-modifi ed PEG hydrogels form fi bers in aqueous solution 
that are able to cross-link forming transient supramolecular 
networks. Here, we show that this unique UPy-transient net-
work is pH responsive, which enables a sol-to-gel switch in a 
subtle pH range, and therefore is compatible with the NOGA 
catheter system. The natural pH of the tissue instantaneously 
transforms the injected solution into a drug-loaded hydrogel 
reservoir. Local in vivo delivery of MRI contrast agents, and 
active growth factors (GF) hepatocyte growth factor (HGF) and 
insulin-like growth factor-1 (IGF-1) is demonstrated in a large 
animal model of ischemic heart disease. 
 2. Results and Discussion 
 2.1. Sol-to-Gel pH-Switching Behavior 
 Our supramolecular UPy-hydrogel can be made fl uid at basic 
pH, with a threshold at pH 8.5, and reversibly transferred back 
into a gel state at neutral pH (Figure  1 B). This allows the basic 
polymer solution to be injected in a solution of neutral pH 
(Figure  1 C). Almost instantaneous gelling of the polymer mate-
rial was observed upon the experienced pH drop. Rheology was 
performed to investigate the material properties of the hydrogel 
before and after pH switching (Figure  1D ) and demonstrated 
that the mechanical properties of the restored hydrogel after pH 
switching are identical to the gel before switching. Furthermore, 
the storage modulus of the 10 wt% UPy-10k gel matches the 
mechanical stiffness of the natural cardiac tissue, e.g., 24 kPa 
for the UPy-hydrogel, versus 26 kPa for adult rat heart muscle [ 33 ] 
(Figure  1D ). In addition, the UPy-hydrogels show self-healing 
behavior (Figure  1F ). UPy-hydrogels behave liquid-like at larger 
deformations ( G ′  <  G ″ ), but recover within minutes when the 
deformation is removed (Figure  1 F). Viscosity measurements on 
the basic UPy-10k polymer solution show a viscosity of 0.8 Pa s 
(Figure  1E ), which is very low for a polymer solution and in the 
same order of magnitude of a solution of plain PEG (without 
UPy-moieties). [ 34 ] After neutralization of the sample, immedi-
ately a gel-like sample is formed, confi rming the macroscopic 
observations (Figure  1 C). This makes our UPy-hydrogelator an 
ideal catheter-injectable material. Since the sol–gel transition is 
fast, we propose that the pH switchability is caused by breaking 
of the cross-links between the fi bers that form the transient net-
work instead of complete disassembly of the fi bers. This results 
in the fast switching behavior shown. Cartoons are shown to 
clarify the assembly (and disassembly) process ( Figure 2A – D ). 
1D UPy-stacks in water are formed by UPy dimerization and 
stacking by additional lateral hydrogen bonding provided by 
the urea-moieties surrounding the alkyl spacers (that form a 
hydrophobic pocket) (Figure  2 A). These stacks cluster together 
to form a hierarchical fi ber (Figure  2A and B ), which entangles 
and cross-links into a transient network, forming a hydrogel 
above the gelation onset (Figure  2 C and D). The UPy–UPy 
interactions are inherently dynamic, thus can dynamically asso-
ciate and dissociate in the assembled fi ber forming the cross-
links that build up the network (Figure  2 C). 
 As stated above, under basic conditions, these cross-links 
are broken leading to disintegration of the transient network. 
To investigate this hypothesis in more detail, we studied the 
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hydrogelator morphology at nanometer level using cryo-trans-
mission electron microscopy (cryo-TEM), atomic force micros-
copy (AFM), dynamic light scattering (DLS), and Fourier-trans-
formed infrared (FT-IR) spectroscopy both at neutral and basic 
conditions. Cryo-TEM shows the presence of rigid and elongated 
fi bers in both neutral and basic solution, with average lengths 
of 75 and 104 nm, respectively (Figure  2E and F , Supplementary 
Information). This shows that a high pH does not infl uence the 
fi ber formation. AFM imaging shows a hierarchical assembly of 
fi bers for the polymers in water (Supplementary Information). 
In the basic pH sample, the assemblies seem more rigid and 
the variation in height is signifi cantly less than in the neutral 
assembly, suggesting that the fi bers are assembled out of fewer 
individual stacks. This indeed indicates a disrupted lateral 
 Figure  1 .  Structure, pH behavior, and rheological properties of UPy-hydrogelator polymers. A) Structure of the UPy-hydrogelators with the hydrophilic 
PEG block ( n  = 227/454,  M n  = 10/20 kDa) in blue and the UPy-alkyl-urea end groups in red. B) Overview of the pH-dependent behavior at a pH range 
from 7 to 9.5. C) Injection of a liquefi ed 10 wt% UPy-10k sample in PBS (colored in red) into a neutral PBS solution. Immediate gelation occurs when 
the basic solution comes in contact with the neutral solution. D) Rheology measurements of a 10 wt% UPy-10k gel before and after the pH switch. 
E) Viscosity measurement of the liquefi ed 10 wt% UPy-10k gel matching the state upon catheter injection. F) Dynamic strain amplitude test of 10 wt% 
UPy-10k gel at 37  ° C showing the self-healing behavior over four cycles. 
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self-assembly due to loss of cross-linking in the basic state. 
Furthermore, DLS confi rms the cryo-TEM measurements. DLS 
demonstrates the presence of two distinct distributions, which 
are proposed to be fi bers and micelles, in both the neutral and 
basic pH environment (Figure  2 G). The size dimensions calcu-
lated using the Stokes–Einstein equation to translate diffusion 
to hydrodynamic radius (with the assumption of spherical and 
noninteracting particles) match the cryo-TEM measurements. 
The breaking of the cross-links, and therefore the sol–gel transi-
tion, is proposed to be the result of deprotonation of the UPy-
moiety when present in the enol-tautomer, yielding the enolate 
(Figure  2H ). FT-IR confi rms this enolate-formation (Figure  2 I). 
Modeling of the tautomeric states of the UPy-moiety in various 
pH environments shows a p K a of the enol-OH of  ≈ 7.2, and 
the enolate anion being the dominant species present in a pH 
range from 8.5 to 12.5. [ 35 ] Upon dissociation, the UPy-group 
experiences a different environment than inside the fi ber and a 
change in tautomeric form occurs, affecting the stability of the 
assembled system. The charged species cannot get incorporated 
back in the UPy-fi ber to form a cross-link to stabilize the UPy-
hydrogel. The preservation of molecular ordered fi brillar assem-
blies forms the fundamental origin of this hydrogel material. As 
a second hierarchy in order, the switching between gel-like and 
solution-like material results from the spatiotemporal formation 
of pH-sensitive interfi ber cross-links. It is this combination of 
selective, hierarchical responsiveness that renders our material 
unique in its kind, and enables catheter injection to be explored 
for in vivo application. 
 2.2. Biocompatibility In Vitro 
 Cell compatibility is essential for the system to be applicable 
in.vivo. The hydrogelator formulation needs to be biocom-
patible both at neutral and basic pH. The pH effect of dif-
ferent buffers on cardiomyocyte progenitor cells (CMPC) was 
screened, being milliQ, 0.9% NaCl, and PBS, all buffers at 
both neutral and basic pH (Supplementary Information). No 
toxicity was observed for the UPy-10k hydrogels prepared in 
different buffers at a physiological pH. For the elevated pH 9 
preparations, only the UPy-hydrogel based on PBS did not 
show any signs of cell toxicity. These in vitro studies show that 
the hydrogel system at both neutral (gel-state) and elevated pH 
(sol-state) in PBS is biocompatible. Additionally, biomaterials 
used for in vitro or in vivo applications need to be free of con-
taminating bacteria and endotoxins. To evaluate the presence of 
lipopolysaccharides present in our materials, an endotoxin test 
was performed. The concentration of endotoxin for all samples 
prepared in PBS was below the FDA approved endotoxin value 
of 0.5 EU mL  − 1 (Supplementary Information). 
 Figure  2 .  Structural analysis of UPy hydrogelators in neutral and basic environment. A–D) Proposed schematic molecular picture of the hydrogel mate-
rial: zoom into the hydrogel fi bers. A) Fibers are composed of multiple UPy-stacks (red), surrounded by a hydrophilic PEG corona (blue). B) Fibers can 
align and C) cross-link by UPy-polymers from one fi ber into a neighboring fi ber. D) UPy-fi bers assemble into a transient network. E and F) Cryo-TEM 
of 1 wt% solution of UPy-20k demonstrates the existence of elongated fi bers in both E) neutral and F) basic environment. G) DLS on 1 wt% UPy-20k 
solutions at various temperatures indicate the presence of two distinct populations in solution, micelles, and fi bers, for both pH conditions. H) UPy-
tautomeric forms: the keto-tautomer and the enol-tautomer can form homodimers, whereas the enolate formed after deprotonation cannot dimerize. 
I) FT-IR on UPy-10k solutions of the C  O stretch vibration indicating the existence of the enolate at basic conditions. 
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 2.3. Growth Factor Incorporation and Release 
 Stimulation of endogenous cardiac repair through GF injec-
tion can benefi t signifi cantly from a sustained release over time 
instead of a single bolus injection. [ 36 , 37 ] Data from different 
preclinical studies show the ability of selected GF, HGF and 
IGF-1, to enhance endogenous cardiac stem cell response to an 
ischemic site of injury. [ 38–40 ] Here, both HGF and IGF-1 were 
incorporated in the UPy-10k hydrogel, and their release pro-
fi le was subsequently studied in.vitro. A prolonged HGF and 
IGF-1 release from the UPy-hydrogel was achieved during 7 d 
( Figure 3A ). The release of HGF was characterized by an ini-
tial outburst of 41%, followed by a sustained release until 97% 
was released by the end of day 4. For IGF-1, 27% was initially 
released whereas subsequent release showed similar release 
kinetics as HGF, with a 94% release by day 4. The difference 
in burst release between the different GF proteins might be 
attributed to the difference in size, which is 103 kDa for HGF 
and 17 kDa for IGF-1, respectively. Since PEG is nonfouling, 
we propose that there are no aspecifi c noncovalent interac-
tions between the proteins and the hydrogel, suggesting that 
the difference in release can only be attrib-
uted to a size-dependent release profi le. Fol-
lowing incubation in the basic UPy-hydrogel 
both IGF-1 and HGF showed preserved bio-
activity shown by their affi nity and ability to 
phosphorylate their corresponding receptors 
IGF-1R and cMET in CMPC (Figure  3 B). 
Furthermore, after 7 d of in vitro incubation, 
the UPy-10k hydrogel was visually still pre-
sent, indicating the stability of the hydrogel. 
 2.4. Intramyocardial Delivery 
 After the initial studies in,vitro, we assessed 
the feasibility of intramyocardial delivery in 
a porcine model of myocardial infarction. In 
total, four injections of 0.2 cc were placed in 
one heart: two injections with SPIOS-labeled 
UPy-10k hydrogel in the anteroseptal wall 
of the left ventricle and two injections with 
UPy-hydrogel loaded with human recom-
binant HGF/IGF-1 in the lateral (infarcted) 
wall. These injections were guided to the 
borderzone of the infarction based on elec-
tromechanical mapping (EMM) ( Figure 4A 
and B ). Six hours after injection, the labeled 
UPy-hydrogel was successfully visualized by 
cardiac MRI (Figure  4 A), and subsequently 
by histological analysis (Supplementary 
Information). With regard to safety issues, 
we observed no cardiac arrhythmias or tam-
ponade within 6 h after the injection. Next, 
we assessed the GF distribution within the 
pig heart by quantifying the human-specifi c 
HGF and IGF-1 at the injection site in the 
infarct borderzone and in the opposite septal 
wall (i.e., remote area). Because of the cross-
reactivity with endogenous porcine HGF, only human specifi c 
IGF-1 was successfully identifi ed at the site of injection (border-
zone) and in the septal wall of the right ventricle (remote area) 
(Figure  4 C and D). These data suggest an effective intramyo-
cardial gradient of GF, increasing toward the borderzone of the 
infarction. Attraction of endogenous cardiac stem cells toward 
the infarct borderzone has shown to be benefi cial for recovery 
in terms of improved blood fl ow to the infarcted area and for-
mation of new viable cardiomyocytes. [ 38 ] These in vivo data 
show feasibility of the UPy-hydrogel system as intramyocardial 
drug carrier and appears to be safe on short term follow-up, up 
to 6 h. 
 2.5. Growth Factor Induced Cardiac Repair and Adverse 
Remodeling 
 The effect of UPy-hydrogel-mediated release on HGF/IGF-1 
treatment in a porcine model of chronic ischemia was eval-
uated. Four weeks after an acute myocardial infarction, 
10 NOGA guided injections were intramyocardially placed in 
 Figure  3 .  Release profi le and bioactivity of HGF/IGF-1 embedded in the UPy-hydrogel. A) In 
vitro release characteristics of IGF-1 and HGF from the UPy-hydrogel by daily collection 
of medium at 37  ° C. Both HGF and IGF-1 display an initial outburst (5 min after start of 
the experiment) followed by a 4-d release. B) Western blot analysis showing that CMPC 
express IGF-1R and cMET receptors that can be activated by IGF-1 (100 ng mL  − 1 ) and HGF 
(100 ng mL  − 1 ), respectively. At both pH levels, pristine UPy-hydrogel did not cause phospho-
rylation of IGF-1R (p-IGF-1R) and cMET (p-cMET). Medium collected from release studies 
of UPy-hydrogel loaded with HGF/IGF-1 show that the released HGF and IGF-1 can still 
activate their receptors, both in UPy-hydrogel with a pH 7.4 (neutral) and the injectable 
pH 9 (basic). 
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 3. Conclusions 
 Here we showed the development of a 
synthetic pH-switchable supramolecular 
hydrogel that is injectable through the long, 
narrow lumen of a state-of-the-art catheter 
mapping system. The catheter-injected 
hydrogelator solution transforms into a 
locally controlled drug release reservoir 
by immediate gelation upon contact with 
heart tissue and additionally is proposed to 
self-heal at the site of injection. The preser-
vation of molecular ordered fi brillar assem-
blies forms the fundamental origin of this 
hydrogel material. As a second hierarchy 
in order, the switching between gel-like 
and solution-like material results from the 
spatiotemporal formation of pH-sensitive 
interfi ber cross-links. When loaded with 
the GF, HGF and IGF-1, we showed that 
the supramolecular hydrogelator system is 
able to reduce scar collagen in a chronic 
myocardial infarction pig model. To our 
knowledge, this is the fi rst large animal 
study where NOGA catheter injection of a 
synthetic pH-switchable hydrogel system 
loaded with GF for controlled release is 
reported. Because the NOGA™ catheter 
system is currently used in dedicated clin-
ical centers, it will be together with our 
unique pH-switchable hydrogel system 
eminently valuable for the development of 
a novel therapy for treatment of ischemic 
heart disease. [ 41 , 42 ] 
 4. Experimental Section 
 Preparation of UPy-Hydrogels : The UPy-hydrogelators with 
 M n ,PEG  = 10 kg mol  − 1 or  M n ,PEG  = 20 kg mol  − 1 , i.e., UPy-10k and UPy-20k, 
respectively, were synthesized by SyMO-Chem BV, Eindhoven, The 
Netherlands. [ 31 ] For solution studies, i.e., using concentrations of 1 wt%, 
the PEG-20k hydrogel was used since the shorter hydrophilic domain 
of the PEG-10k materials causes precipitation in time. For the gel and 
biomedical experiments, the higher stability of the PEG-10k is preferred 
considering the resulting prolonged lifetime of the gel. 
 Growth Factors and UPy-Hydrogels : For the preparation of the 
hydrogels, polymer solutions were prepared by dissolving 10 wt% in PBS 
pH 7.4 by stirring at 70  ° C for 2 h and subsequently cooled to RT. To 
liquefy the polymer solution, the pH was raised by adding 2  μ L aliquots 
of a 0.1  M NaOH stock solution. Human recombinant IGF-1 (Miltenyi 
Biotec) and human recombinant HGF (Miltenyi Biotec) were mixed in 
by slow stirring for 10 min yielding a fi nal concentration of 500 ng mL  − 1 
of each GF. For noninvasive assessment of the UPy-hydrogel by cardiac 
MRI in,vivo, SPIOS were mixed with UPy-hydrogel pH 9 by gentle 
stirring at room temperature for 3 min yielding a fi nal concentration of 
13.6  μ g mL  − 1 . Solutions were then UV-sterilized for at least 1 h before 
use. 
 Rheology Experiments on Gel Samples : Oscillatory rheology 
experiments were performed on an Anton Paar Physica MCR 501 
rheometer. Mechanical properties of the viscoelastic hydrogel material 
under neutral or neutralized conditions were assayed using a parallel 
the infarct borderzone. Three treatment groups were tested, 
consisting of the pristine UPy-10k hydrogel, HGF/IGF-1 in 
saline, and UPy-10k hydrogel loaded with HGF/IGF-1. Four 
weeks after injection, no adverse events (e.g., fever, cardiac 
arrhythmias, shortness of breath) were recorded during 
follow-up, and liver and renal functions were comparable in 
all groups (data not shown). The myocardial scar tissue was 
visualized by 1% triphenyl-tetrazolium chloride. All treat-
ment groups macroscopically and histologically displayed 
roughly similar scar tissue formation in the lateral wall of 
the left ventricle ( Figure 5A –C  and  5G –I). However, after 
quantifi cation of the Picrosirius Red stained tissue slices 
(Figure  5D –F and  5 J–L) it was shown that the collagen con-
tent of the infarct scar in the UPy-hydrogel loaded with HGF/
IGF-1-treated animals was reduced (12.9  ± 3.1%) compared 
with the pristine UPy-hydrogel (25.2  ± 5.7%;  P  = 0.02) (Figure 
 5 P). Remarkably, patched-like clusters of viable myocardium 
were present dispersed in between the dense collagen fi bers 
in the UPy-hydrogel-loaded HGF/IGF-1 group (Figure  5 I). 
These results suggest a more favorable remodeling process 
in the UPy-hydrogel loaded with HGF/IGF-1 than in soluble 
HGF/IGF-1-treated animals. 
 Figure  4 .  Transendocardial injection of UPy-hydrogel loaded with HGF/IGF-1. A) Cardiac MRI 
short axis plane showing the UP-gel containing SPIOS, visible as focal depressed T2 ∗ intensity, 
indicated by the yellow arrow. B) Electromechanical mapping of the left ventricle indicating 
the UPy-hydrogel  + HGF/IGF-1 injections (white arrows) in the borderzone of the infarct (red 
signal, defi ned as  < 6% on the local linear shortening map). C) Western blot analysis of human 
IGF-1 in the myocardial borderzone injected with pristine UPy-hydrogel, or UPy-hydrogel  + HGF/
IGF-1 injected into the borderzone (BZ). After transendocardial injection, human IGF-1 was also 
detected in the opposing septal wall of the right ventricle (Remote). Ponceau S was used as a 
loading control to correct for differences in protein quantity. D) Immunofl uorescent labeling of 
human IGF-1 (in green) shows cytoplasmatic and predominately perinuclear uptake by cardio-
myocytes. Alfa-sarcomeric actin is shown in red. Nuclei are stained by HOECHST (blue). 
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(PP 25)-plate geometry. The linear viscoelastic regime of the samples 
was obtained from amplitude sweep experiments that were from 
0.1% to 1000% strain at 1 rad s  − 1 angular frequency. Frequency sweep 
measurements were recorded from 0.1 to 100 rad s  − 1 at 1% strain. 
Measurements were performed at 20 ° C unless stated otherwise. 
 Viscosity Measurements on Basic Solution : Steady-state viscosity 
measurements were performed using a cone (CP-25-1) -plate geometry 
with a 1 ° angle. UPy-10k was dissolved in PBS buffer (pH 7.4) at 70 ° C, 
cooled to room temperature and transferred to the injectable fl uid state 
by addition of a small aliquot of NaOH, yielding a 10 wt% hydrogel. The 
viscosity as a function of shear rate ( γ.  ) was measured from 0.1 to 100 
rad s  − 1 at 20 ° C. The zero-shear viscosity,  η 0, was extrapolated from the 
Newtonian plateau to the  y -axis. 
 Cryogenic Transmission Electron Microscopy : Sample preparation was 
performed by pipette addition of 1 wt% UPy-20k solutions (3  μ L; neutral 
and basic conditions) onto holey carbon fi lm (hole diameter  = 2  μ m) 
supported by a copper TEM grid before manual blotting at 100% relative 
humidity and 21 ° C. Immediate vitrifi cation was performed by automated 
 Figure  5 .  Adverse remodeling and GF induced cardiac repair. A–C) The infarct scar is visible 
as a white color stained with 1% triphenyl-tetrazolium chloride in all three treatment groups; 
A) pristine UPy-hydrogel, B) HGF/IGF-1, and C) UPy-hydrogel  + HGF/IGF-1. A–C) Scale bars 
represent 3.0 cm. D–F/J–L) Cryosections were stained with Picrosirius Red to quantify collagen 
deposition using polarized light on the infarct zone D–F) and the remote area showing viable 
myocardium with scarcely dispersed collagen J–L). G–I/M–O) The bright fi eld images of the 
Picrosirius Red staining. I) Patches of cardiomyocytes were observed within the infarct zone 
in the UPy-hydrogel  + HGF/IGF-1-treated group (demarcated areas). P) Quantifi cation of total 
collagen content per fi eld demonstrates reduced collagen content in the infarct scar in the 
UPy-hydrogel  + HGF/IGF-1 compared with the UPy-hydrogel ( ∗ denotes  P  = 0.02). The data 
are expressed as mean  ± SEM. Differences in data were evaluated with a one-way analysis of 
variance (ANOVA) followed by Tukey post-hoc analysis. D–O) Scale bars represent 500  μ m. 
plunging of the grid into liquid ethane. Upon 
completion of the set time, automated vitrifi cation 
was performed. Samples were stored under liquid 
nitrogen before imaging. Cryo-TEM was performed 
on a FEI Tecnai 20 (type Sphera) TEM operating 
with a 200 kV LaB6 fi lament and a bottom mounted 
1024  × 1024 Gatan msc 794™ CCD camera. 
 Dynamic Light Scattering : DLS experiments on 
a 1 wt% UPy-20k solution under neutral and basic 
conditions were conducted on an ALV/CGS-3 
MD-4 compact goniometer system equipped with a 
multiple tau digital real-time correlator (ALV-7004) 
(solid state laser:  λ  = 532 nm; 40 mW). Typical 
experiments covered a scattering angle from 20 ° to 
150 ° , averaging over 5  × 30 s runs at a temperature 
of 20–40 ° C in 10  ° C intervals. Data were processed 
using after ALV freeware and scattering artifacts 
were excluded from the analysis. The hydrodynamic 
radius ( R h ) was extracted from the measured 
diffusion coeffi cient  D 0  =  Γ ( x )/ q 2 assuming validity 
of the Stokes–Einstein relation,  R h  =  kT / 6 π η D 
( k being the Boltzmann constant and  η the solvent 
viscosity) for spherical objects. 
 Infrared Spectroscopy : UPy-10k samples (neutral 
and basic conditions) were prepared with a total 
concentration of 1 wt% in D 2 O. Solution infrared 
spectra were recorded on a PerkinElmer spectrum 
One FT-IR spectrometer and measured at a resolution 
of 4 cm  − 1 , by coadding 128 scans. Samples were 
loaded in a fi xed path length (50  μ m) cell with CaF 2 
windows, and used immediately for IR measurements. 
 Cell Culture Experiments and Biocompatibility 
Testing : CMPC derived from human fetal hearts 
were isolated as described. [ 43 ] Briefl y, human fetal 
hearts were collected following elective abortion, 
after written informed consent was provided. 
The protocol was approved by the Medical Ethics 
committee of the University Medical Center 
Utrecht and is in line with the principles outlined 
in the Declaration of Helsinki. Briefl y, the CMPC 
were isolated by magnetic bead sorting using 
Sca-1 coupled beads (Milteny). CMPC were then 
maintained in growth medium and used for 
different assays. The toxicity of UPy-10k hydrogel 
formulations on CMPC was tested in vitro using 
a lactate dehydrogenase (LDH) assay (Sigma–
Aldrich). CMPC were cultured in M-199 medium 
(Sigma–Aldrich) with 2% FBS (Invitrogen) and 
incubated with 100  μ L of 10 wt% UPy-hydrogel 
based on milliQ, NaCl 0.9 or PBS (all buffers were 
tested both at pH 7.4 and pH 9.0). After 3 d of incubation, medium 
was collected and tested for the presence of LDH as a marker for cell 
damage according to manufacturer’s instruction. 
 Growth Factor Release and Bioactivity In Vitro : Human recombinant 
HGF and human recombinant IGF-1 dissolved in milliQ water were 
added to liquefi ed UPy-10K hydrogel in PBS pH 9 yielding a fi nal 
concentration of 500 ng mL  − 1 of each GF. 100  μ L of UPy-hydrogel with 
GF was incubated in 200  μ L of medium in 48-well plates on a rotational 
shaker (90 rpm) at 37 ° C for 7 d. 75  μ L of medium was removed daily 
and replaced with fresh medium. The collected medium was quantifi ed 
for HGF and IGF-1 using ELISA detection (R&D Systems). The bioactivity 
of the GF released was investigated as follows: CMPC were subjected 
to serum starvation for 18 h, followed by supplementation of medium 
collected from the HGF/IGF-1 release study for 15 min. Cells were lysed 
and Western blot analysis was performed for phosphorylated cMET for 
HGF (Cell Signaling) and phosphorylated IGF receptor 1 (pIGF-R1) for 
IGF-1 (Cell Signaling). IGF-1 (100 ng mL  − 1 ) and HGF (100 ng mL  − 1 ) 
dissolved in MilliQ water served as a positive control. 
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 Animal Experiments and Study Design : In total thirteen pigs (female 
Dutch landrace, weighing approximately 70 kg) received humane care 
in compliance with the national guidelines on animal care and prior 
approval by the Animal Experimentation Committee of the Faculty of 
Medicine, Utrecht University, The Netherlands. Myocardial infarction was 
induced by 75 min of intracoronary balloon occlusion of the proximal left 
circumfl ex artery. Four weeks later, the animals underwent 3D EMM of the 
left ventricle for infarct and borderzone localization using the NOGA™ 
catheter system (Biosense Webster, Cordis, Johnson & Johnson, USA). 
Intramyocardial delivery was performed using the NOGA™ Myostar 
system (Biosense Webster, Cordis, Johnson & Johnson). 
 Short-Term In Vivo Tracking of Growth Factor Distribution : Regarding the 
in vivo tracking of UPy-hydrogel, four injections of 0.2 cc were placed, two 
injections with SPIOS-labeled UPy-10k hydrogel in the anteroseptal wall of 
the left ventricle and two injections with HGF/IGF-1-loaded UPy-hydrogel 
to the borderzone of the infarction (lateral wall). Six hours after injection, 
two animals underwent in vivo tracking of the hydrogel by cardiac MRI. 
Tissue samples collected from the septal wall and the injection site were 
snap frozen for western blot analysis for human IGF-1 (Abcam; dilution 
1:1000) and immunofl uorescent staining for human anti-IGF-1 (Abcam; 
dilution 1:100) and for alfa-sarcomeric actin (Sigma, dilution 1:50). 
 The Effect of Sustained Release on Cardiac Function : Four weeks 
after myocardial infarction induction 10 animals were injected with 
pristine UPy-10k hydrogel ( n  = 3), saline dissolved HGF/IGF-1 (both 
500 ng mL  − 1 ) ( n  = 3) and UPy-hydrogel loaded with HGF/IGF-1 (both 
500 ng mL  − 1 ) ( n  = 4). Then, the animals were followed for 4 weeks, and 
subsequently euthanized by exsanguination under general anesthesia. 
After excision of the heart, the heart was cut into fi ve slices from base 
to apex and infarct size was determined by 1% triphenyl-tetrazolium 
chloride staining. Tissue samples collected of the septal wall (remote) 
and the infarction zone were snap frozen for histological analysis. 
Cryosections (7  μ m) were prepared on a microtome (Leika) and fi xed 
in 4% formalin for 10 min. Next, the sections were incubated in 0.1% 
Sirius red (BDH) in picric acid (Sigma) for 8 min at room temperature. 
After counterstaining the nuclei with hematoxylin for 1 min, the sections 
were dehydrated, cleared, and mounted. The quantifi cation was 
performed on 30 fi elds per animal of UV polarized light on a microscope 
(Olympos DP71) at 40 × magnifi cation and automatically quantifi ed for 
the percentage of collagen per fi eld using ImageJ software for Macintosh 
(version 1.44g). The analysis was performed by an investigator blinded 
to the treatment allocation. 
 Statistical Analysis : The data are expressed as mean  ± SEM. 
Differences in data were evaluated with a one-way ANOVA followed by 
Tukey post-hoc analysis. Data analysis was performed on SPSS v19.0.0 
software for Macintosh. Probabilities of  P  < 0.05 were considered to be 
statistically signifi cant;  P  < 0.05 is depicted as  ∗ . 
 Supporting Information 
 Supporting Information is available from the Wiley Online Library or 
from the author. 
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